Prodesse Flu Assay Gets Additional FDA Claims | GenomeWeb
NEW YORK (GenomeWeb News) – Molecular diagnostics company Prodesse said today that the US Food and Drug Administration has authorized two changes to the packaging on the company’s influenza assay.
 
The FDA, which cleared the company’s ProFlu+ at the beginning of 2008, has accepted using the bioMérieux NucliSENS easyMAG automated nucleic acid extraction system with the ProFlu+ test, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.